NASDAQ · Biotechnology

CRNX (CRNX) Stock

$84.95 +0.00% NASDAQ: CRNX Healthcare

Valuation

MetricValue
Price$84.95
Market Cap$9.00B
P/E Ratio-16.80
P/B Ratio7.51
P/S Ratio213.26
EPS (TTM)$0.00
52-Week High$84.99
52-Week Low$31.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-44.22%
ROA-37.95%
ROCE-44.21%
Gross Margin-6450.00%
Operating Margin-13.08%
Net Margin-27.47%
Debt/Equity0.04
Current Ratio18.60

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$5.0M$4.0M$1.0M$8.0M
Operating Profit$-108.0M$-168.0M$-223.0M$-339.0M$-517.0M
Net Profit$-108.0M$-164.0M$-215.0M$-298.0M$-465.0M
EPS$-2.80$-3.15$-3.69$-3.69$-4.95
Op Margin-9990.9%-3544.1%-5547.2%-32613.5%-6714.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$351.0M$352.0M$635.0M$1.4B$1.1B
Total Liabilities$19.0M$36.0M$96.0M$110.0M$143.0M
Cash$201.0M$33.0M$55.0M$265.0M$102.0M
Borrowings$4.0M$3.0M$52.0M$52.0M$49.0M

Latest News

Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy? Motley Fool · Jul 13, 2026 Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse MarketBeat · Jul 11, 2026 Why This Pharmaceutical Stock Jumped Close to 100% This Week Motley Fool · Jul 10, 2026 Why Crinetics Stock Soared 99% This Week 24/7 Wall St. · Jul 9, 2026 Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says MT Newswires · Jul 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-89.0M$-115.0M$-166.0M$-226.0M$-378.0M
Investing Cash Flow$-57.0M$-176.0M$-205.0M$-579.0M$168.0M
Financing Cash Flow$3.0M$5.0M$20.0M$40.0M$0
Net Cash Flow$108.0M$-167.0M$22.0M$210.0M$-164.0M
Free Cash Flow$-89.0M$-117.0M$-171.0M$-230.0M$-384.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.83
EV / EBITDA-17.65
FCF Yield-4.73%
Quick Ratio15.53
Interest Coverage—
Return 1Y155.11%
Return 3Y387.10%
Return 5Y262.25%

Ownership

Insiders Held1.59%
Institutions Held119.81%
Institutions Float Held121.75%
Institutional HolderSharesReport Date
FMR, LLC15,759,7992026-03-31
Blackrock Inc.8,478,8152026-03-31
Farallon Capital Management LLC8,338,0982026-03-31
Wellington Management Group, LLP8,157,2042026-03-31
Driehaus Capital Management, LLC6,395,9222026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACADACADIA Pharmaceuticals Inc. $19.73 -2.86% 8.87 $3.40B 0.00%
AKROAkero Therapeutics, Inc. $54.65 +0.00% -19.87 $4.50B 0.00%
DYNDyne Therapeutics, Inc. $15.62 -0.95% -4.84 $2.92B 0.00%
IMVTImmunovant, Inc. $28.41 -2.37% -11.98 $5.87B 0.00%
KYMRKymera Therapeutics, Inc. $110.76 -0.08% -34.00 $9.11B 0.00%

About CRNX

CRNX is led by CEO R. Scott Struthers, employs 594 people, headquartered in San Diego, US, publicly traded since 2018.

CRNX stock trades at $84.95 with a market capitalization of $9.00B. The stock is valued at a negative price-to-earnings (P/E) ratio of -16.80, reflecting a net loss over the last twelve months, price-to-book of 7.51, price-to-sales of 213.26. Over the past 52 weeks the stock has ranged between $31.00 and $84.99, and currently trades at or near its 52-week high.

On profitability, CRNX generates a return on equity (ROE) of -44.22% (negative, reflecting a net loss), return on capital employed of -44.21%, an operating margin of -13.08%, a net profit margin of -27.47%.

CRNX by the numbers, 2016–2025

Between 2016 and 2025 CRNX reported revenue of $1.0M rising to $8.0M, a change of +700.0% across 10 years. Compounded, revenue has grown —% a year over five years, 17.0% over three, 700.0% over the last twelve months. Net profit fell to $-465.0M.

Operating margin went from -1026.2% in 2016 to -6714.8% in 2025, a fall of 5688.6 percentage points. The most recent net margin is -27.47%. On a trailing twelve-month basis to Jun '26, revenue is $42.0M and net profit $-502.0M.

Borrowings stand at $49.0M, cash from operations was $-378.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -38.7% over five years, and was -46.9% in the most recent year.

The share price itself has compounded at 18.4% a year over five years, 18.5% over three, 10.8% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

CRNX (CRNX) — frequently asked questions

What is CRNX (CRNX) stock price today?

CRNX (CRNX) is currently trading at $84.95, up 0% today.

What is CRNX P/E ratio?

CRNX's P/E ratio is -16.80. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is CRNX return on equity (ROE)?

CRNX's return on equity (ROE) is -44.22%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is CRNX's market cap?

CRNX has a market capitalization of $9.00B.

Does CRNX pay a dividend?

CRNX is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does CRNX carry?

CRNX has a debt-to-equity ratio of 0.04. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is CRNX's profit margin?

CRNX reports a net profit margin of -27.47% — the share of revenue left after every cost, including tax and interest.

What sector is CRNX in?

CRNX is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is CRNX listed on?

CRNX trades on NASDAQ under the ticker CRNX.

What is CRNX's 52-week range?

Over the last year CRNX has traded between $31.00 and $84.99.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens CRNX currently matches

On the figures above, CRNX passes the filters for 7 of our ready-made screens, among them Low Debt Stocks, Debt Free Stocks Under $100, Debt Free Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Low Debt StocksDebt Free Stocks Under $100Debt Free StocksStocks Under $100Mid Cap StocksDebt to Equity Below 1 StocksHigh Current Ratio Stocks

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.